Term ends Nov 9, 2030 · High confidence
20-year base term ends Nov 10, 2029
Held by Arbutus Biopharma Corporation
Filed Sep 7, 2011 as application 13/128,287 · Granted Apr 7, 2015
Base term plus 364 days of patent term adjustment (USPTO delay)
Today
2009
2030
Clock starts
Nov 10, 2009
Nov 10, 2009
Term ends
Nov 9, 2030
Nov 9, 2030
Granted
Apr 7, 2015
Apr 7, 2015
base term
patent term adjustment
fee events
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
364
Days of term adjustment
Read from the USPTO patent term adjustment record, not recalculated here.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
7
Family applications on record here
Applications sharing this one's continuity chain, as the file histories and patent records this site holds name them. The family may have others.
This patent's term runs 364 days past its 20-year base term on prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Nov 10, 2009, when application PCT/US2009/063931, the earliest non-provisional in its chain, was filed (this one was filed Sep 7, 2011) | Nov 10, 2029 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | +364 days, USPTO patent term adjustment record | Nov 9, 2030 | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Nov 9, 2030 | High confidence |
This family
| Application PCT/US2009/063931 | PCT application no patent term | no patent term |
| US 8,999,351 | this patent Nov 2030 | Nov 2030 |
| US 9,682,139 | Lapsed on the fee record Jun 2025 | Jun 2025 |
| US 10,117,941 | Grace period ended Nov 2029 | Nov 2029 |
| US 10,821,186 | In force Nov 2029 | Nov 2029 |
| Application 17/065,208 | Abandoned not computed | not computed |
| Application 18/110,791 | Abandoned not computed | not computed |
Every application listed has its file history here. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Sep 8, 2011 Reel 26870, frame 15 | Manoharan, Muthiah; Rajeev, Kallanthottahil G.; Jayaraman, Muthusamy; Butler, David; Narayanannair, Jayaprakash K.; Maier, Martin; Eltepu, Laxman | Alynylam Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Feb 21, 2013 Reel 29852, frame 306 | Alnylam Pharmaceuticals, Inc. | Tekmira Pharmaceuticals Corporation | Assignment of Assignor's Interest |
| Oct 27, 2016 Reel 40154, frame 419 | Tekmira Pharmaceuticals Corporation | Arbutus Biopharma Corporation | Change of Name |
| Jul 27, 2018 Reel 46640, frame 764 | Protiva Biotherapeutics Inc.; Arbutus Biopharma Corporation | Arbutus Biopharma Corporation | Merger and Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Nov 2030
Term ends Nov 9, 2030. No further fees fall due before then
Note
The 364 days of patent term adjustment (USPTO delay) are read from the USPTO record, not recalculated by us
Citations
231
later US patents cite this one
That is top 5% of utility patents granted in 2015 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.